logo

Ardelyx, Inc (ARDX)



Trade ARDX now with
  Date
  Headline
4/25/2022 7:13:58 AM Ardelyx Announces FDA Plan To Convene Advisory Committee For XPHOZAH
4/11/2022 7:04:56 AM Ardelyx And Kyowa Kirin Amend License Agreement For Tenapanor
4/7/2022 8:03:08 AM Ardelyx Presents Positive Data Further Supporting Efficacy And Safety Of XPHOZAH
4/4/2022 8:13:55 AM Ardelyx Announces US Launch Of IBSRELA, New First-in-Class Treatment For IBS-C In Adults
2/24/2022 8:10:34 AM Ardelyx Announces $27.5 Mln Debt Financing Agreement With SLR Capital Partners
11/12/2021 8:21:59 AM Ardelyx, Inc. Q3 Net Loss $43.6 Mln Vs. Net Loss $18.1 Mln Last Year
10/13/2021 8:13:21 AM Ardelyx Continues To Await Clarity From FDA On Path Forward For Approval Of Tenapanor For Hyperphosphatemia
9/3/2021 8:04:36 AM Ardelyx Announces Publication Of 52-week Phase 3 PHREEDOM Trial In American Society Of Nephrology Journal, Kidney360
8/13/2021 8:04:21 AM Ardelyx Q2 Net Loss $45.2 Mln Vs. Loss $25.0 Mln Prior Year
4/14/2021 8:09:37 AM Ardelyx Partner, Kyowa Kirin, Announces Initiation Of Phase 3 Studies Of Tenapanor For Hyperphosphatemia In Japan
4/12/2021 8:21:35 AM Ardelyx To Present Data From NORMALIZE At The ISN World Congress Of Nephrology 2021
3/8/2021 8:08:59 AM Ardelyx FY Loss Narrows To $94.3 Mln From $94.9 Mln Prior Year
11/12/2018 9:31:47 AM Wedbush Is Cutting Ardelyx, Inc (ARDX) FY19 Estimate To -1.78 From -1.74
11/12/2018 9:31:34 AM Wedbush Is Cutting Ardelyx, Inc (ARDX) Q4 19 Estimate To -0.47 From -0.46
11/12/2018 9:31:13 AM Wedbush Is Lowering Ardelyx, Inc (ARDX) Q3 19 Estimate To -0.45 From -0.44